Scpharmaceuticals Stock Today
| SCPH Stock | USD 3.04 0.01 0.33% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Scpharmaceuticals is trading at 3.04 as of the 20th of March 2025. This is a 0.33 percent decrease since the beginning of the trading day. The stock's open price was 3.05. Scpharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of November 2017 | Category Healthcare | Classification Health Care |
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. The company has 50.04 M outstanding shares of which 6.14 M shares are at this time shorted by private and institutional investors with about 22.58 trading days to cover. More on Scpharmaceuticals
Moving against Scpharmaceuticals Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Scpharmaceuticals Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | John Tucker | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsScpharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Scpharmaceuticals' financial leverage. It provides some insight into what part of Scpharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Scpharmaceuticals (SCPH) is traded on NASDAQ Exchange in USA. It is located in 25 Mall Road, Burlington, MA, United States, 01803 and employs 135 people. Scpharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 152.62 M. Scpharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 50.04 M outstanding shares of which 6.14 M shares are at this time shorted by private and institutional investors with about 22.58 trading days to cover.
Scpharmaceuticals currently holds about 55.85 M in cash with (59.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04.
Check Scpharmaceuticals Probability Of Bankruptcy
Ownership AllocationScpharmaceuticals shows a total of 50.04 Million outstanding shares. The majority of Scpharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Scpharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Scpharmaceuticals. Please pay attention to any change in the institutional holdings of Scpharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Scpharmaceuticals Ownership Details
Scpharmaceuticals Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Thrivent Financial For Lutherans | 2024-12-31 | 1 M | |
| Nantahala Capital Management, Llc | 2024-12-31 | 1000 K | |
| Rice Hall James & Associates, Llc | 2024-12-31 | 989.6 K | |
| Kingdon Capital Management Llc | 2024-12-31 | 800 K | |
| Geode Capital Management, Llc | 2024-12-31 | 750.5 K | |
| State Street Corp | 2024-12-31 | 725.1 K | |
| Stonepine Capital Management Llc | 683.5 K | ||
| Tejara Capital Ltd | 2024-12-31 | 612.9 K | |
| Perceptive Advisors Llc | 2024-12-31 | 500 K | |
| Orbimed Advisors, Llc | 2024-12-31 | 6.1 M | |
| Rubric Capital Management Lp | 2024-12-31 | 4.8 M |
Scpharmaceuticals Historical Income Statement
Scpharmaceuticals Stock Against Markets
Scpharmaceuticals Corporate Management
| John PharmD | Senior Affairs | Profile | |
| Rachael Nokes | Principal Accounting Officer | Profile | |
| Katherine Taudvin | Director Relations | Profile | |
| Michael Hassman | Senior Operations | Profile | |
| Steve Parsons | Senior Commercial | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share | Quarterly Revenue Growth 1.641 | Return On Assets | Return On Equity |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.